Sunday, August 1, 2021

Med, Biotech & Pharma

Emerging Growth Medical, Biotechnology and Pharmaceutical Companies

CytoDyn’s (CYDY) Long-Hauler Trial a Resounding Success: Clear Pathway to Approval This Year

Clinically Significant Data in 18 of 24 SymptomsSeeking Breakthrough Therapy Designation in Long-Haulers and CancerDefinitive timeline for HIV BLA Filing by October 2021Dosing of...

CLS Holdings USA, Inc. (OTCQB: CLSH) Achieves Substantial Year-Over-Year Results for May 2021

LAS VEGAS, NV / ACCESSWIRE / June 15, 2021 / CLS Holdings USA, Inc. (OTCQB:CLSH) (CSE:CLSH), the ''Company'' or ''CLS'', a diversified cannabis company operating...

5 Small-Cap Pharma Stocks to Buy in June

While the COVID-19 pandemic has cast doubt on many investments, pharma stocks have never looked better. The need for novel treatments and therapies is...

CytoDyn (CYDY) Conference Call Roundup

After an FDA statement on Monday May 17th, 2021, CytoDyn Inc. (OTCMKTS: CYDY) was indirectly forced to publicly respond to it.  The FDA statement...

Celledex gaining traction on experimental Cancer Vaccine while Avalon Globocare paves the way in...

In other ongoing research looking at cancer vaccines, the Cancer Research Institute, in partnership with the Parker Institute for Cancer Immunotherapy, is studying a combination of a vaccine with the adjuvants Flt3 ligand and poly-ICLC plus the checkpoint inhibitor nivolumab (Opdivo) and standard-of-care radiation in castrate-resistant prostate cancer. Results are expected in the next six to 12 months, said Jill O’Donnell-Tormey, chief executive officer and director of scientific affairs at the Cancer Research Institute.

Marble Arch Research Report Healixa, Inc. (OTC Pink: EMOR)

COMPANY SUMMARY On June 22, 2020, Emerald Organic Products Inc. (OTCPK: EMOR), a Nevada Corporation, changed its name to Healixa Inc., to reflect the company’s...

Some Experts worry about Next-Generation COVID-19 Vaccines , while they know little about Avalon...

We may find out whether this is going to be a problem sooner than you’d think. Moderna NASDAQ: MRNA is working with the National Institute of Allergy and Infectious Diseases — which helped it design its original Covid vaccine — to test an updated version of its vaccine that targets the variant first spotted in South Africa, B.1.351. That variant appears to be able to evade immune responses triggered by earlier versions of the virus.

Healthcare Technology Disruptor Obtains National Reach

Look at Healixa, Inc. (OTC Pink: EMOR)

A sub 100 million market cap company teams up wit MIT in a Co-Development...

Regarding VX-864, its experimental treatment for the rare, inherited lung disease called alpha-1 antitrypsin deficiency, Vertex said a readout of a Phase 2 study is expected in the first half of the year. Last October, Vertex was forced to shelve its first drug for alpha-1 antitrypsin deficiency due to liver toxicity. Independent study monitors are taking regular looks at the safety data from the ongoing VX-864 study, and to date, patient enrollment continues, Vertex said Monday.

Skeptics grow impatient awaiting Cel-Sci to release there Phase 3 data on Cancer drug...

No legitimate reason exists for Cel-Sci to be taking this long, even accounting for Covid. The simple truth is Cel-Sci is trying to bury Multikine’s negative results, as it did previously when independent monitors tried to shut the study down twice, or when the FDA halted the study citing an “unreasonable and significant risk of illness or injury to human subjects.”

Latest News